ELISA News and Research

RSS

High-performance ELISA for serology in mild-moderate non-hospitalized COVID-19

A new study describes an ELISA assay that combines the detection of IgM, IgA, and IgG antibodies against the SARS−CoV−2 trimeric spike glycoprotein.

7 Dec 2020

SARS-CoV-2 D614G mutation does not affect performance of serological assays

In a new study published in The Journal of Infectious Diseases, US researchers considered the emergence of a new SARS-CoV-2 spike protein variant. They compared spike G614-based assay to the original D614-based assay – pointing towards the development of recognizable, cross-responsive humoral immunity.

2 Dec 2020

Chinese woman still sheds SARS-CoV-2 over four months post-infection

A new study by Chinese scientists explore an unusual case of extended viral shedding in a 68-year-old woman up to four months post-infection.

1 Dec 2020

Avacta Group announces significant progress in the development of SARS-CoV-2 rapid antigen test

Avacta Group plc, the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce significant progress in the development of a highly scalable manufacturing process for a lateral flow SARS-CoV-2 antigen test being carried out with BBI Solutions, and that the lateral flow test has very good analytical sensitivity with laboratory samples.

From Avacta Life Sciences Ltd. 24 Nov 2020

Chicago seroprevalence study shows COVID-19 cases 16 times higher than currently predicted

A startling new case study of Chicago, led by a team of researchers at Northwestern University in Illinois, USA, suggests a 16-fold higher incidence of SARS-CoV-2 infection than previously thought. This is judging from seroprevalence (antibody presence blood testing) figures, rather than the number of RT-PCR-positives reported there (via swab sample testing of symptomatic patients).

23 Nov 2020

Anti-SARS-CoV-2 hyperimmune globulin produced from convalescent plasma pool has 3-fold antibody neutralizing activity

In a recent study published in the preprint server bioRxiv, researchers from the Grifols Bioscience Research Group reported on the collection of convalescent plasma and production of anti-SARS-CoV-2 hyperimmune globulin for use in clinical research.

22 Nov 2020

New findings support current and planned clinical trials of Janssen SARS-CoV-2 vaccine

Researchers from the United States and The Netherlands have conducted a pre-clinical study supporting the initiation of a Phase 3 trial to test a two-dose regimen of the Janssen Ad26.COV2.S vaccine candidate among adult and elderly individuals.

19 Nov 2020

Detectable SARS-CoV-2 antibodies 120 days post-infection in Chicago case study

In a recent study, a team of researchers at Northwestern University, USA, had found that nearly 20 percent seroprevalence in the United States metropolitan site, Chicago, over the summer, during a period when lockdown restrictions were eased. They found that three-quarters of seropositive individuals retained detectable antibodies for at least 120 days or four months.

19 Nov 2020

Optimizing SARS-COV-2 inactivation for COVID-19 research at lower biosafety levels

Researchers at Montana State University have validated and compared two methods for inactivating the causative agent of coronavirus disease 2019 (COVID-19) that would enable the virus to be studied at a lower biosafety level (BSL) than the one currently required.

18 Nov 2020

Bioelectronic rapid test for COVID-19

A recent study presents a bioelectronic sensor platform to detect protein at the single-molecule level that is simple, rapid, and robust enough for widespread POC (point-of-care) or bedside application.

18 Nov 2020

SARS-CoV-2 was circulating in Italy before China recognized its existence

This study, published in the Tumori Journal, sheds light on the possibility that the virus had been spreading in Italy well before the outbreak was officially reported in Wuhan, China.

17 Nov 2020

Males may have higher but more transient SARS-CoV-2 immunity than females post-infection

Adding another piece to the puzzle that is coronavirus disease 2019 (COVID-19) serology, a new study published on the preprint server medRxiv* in November 2020 suggests that males have stronger but more transient anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protective immunity than females.

17 Nov 2020

Promising SARS-CoV-2 N epitope for more accurate diagnostic and surveillance antibody testing

A new study published on the preprint server bioRxiv in November 2020 describes the virus's N protein as a promising epitope for serology.

12 Nov 2020

Research tracks humoral immunity response over eight months post COVID-19 infection

Researchers from Chongqing Medical University have tried to answer one of the burning questions regarding the longevity of immune response to coronavirus disease 2019 (COVID-19): How long does immunity last after infection? Their study looked at the lasting effects and continued immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) over eight months after recovery from the infection.

11 Nov 2020

Critically ill COVID-19 patients experience novel platelet-activating immune complexes, study finds

Canadian researchers from McMaster University, Ontario, have pinpointed platelet activating immune complexes in coagulation disorders associated with coronavirus disease 2019 (COVID-19), the condition caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

10 Nov 2020

Lateral flow test enables faster, accurate diagnosis of periprosthetic joint infection

The recently FDA-authorized alpha-defensin lateral flow test is a highly accurate, ten-minute test for diagnosis of periprosthetic joint infection (PJI) - a serious and costly complication of total joint replacement, reports a study in The Journal of Bone & Joint Surgery.

9 Nov 2020

Study suggests herd immunity to COVID-19 in New York City is low

Researchers in the United States have estimated that the proportion of people in New York City who developed antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the first wave of the coronavirus disease 2019 (COVID-19) pandemic is around one in eight.

9 Nov 2020

Study shows SARS-CoV-2 infection four times more likely through household transmission than community

A group of researchers from across the United States working in collaboration with their Swiss counterparts have conducted an extensive population-based serological survey to understand the transmission dynamics of severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) – the novel agent that causes coronavirus disease 2019 (COVID-19).

8 Nov 2020

Cats shed SARS-CoV-2 RNA for a shorter duration compared to humans, study finds

Since the emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronavirus disease 2019 (COVID-19), there have been numerous reports of pets becoming infected. Both dogs and cats have been observed to exhibit symptoms of infection.